dc.contributor.author |
Hacioglu, S |
|
dc.contributor.author |
Bilen, Y |
|
dc.contributor.author |
Eser, A |
|
dc.contributor.author |
Sivgin, S |
|
dc.contributor.author |
Gurkan, E |
|
dc.contributor.author |
Yildirim, R |
|
dc.contributor.author |
Aydogdu, I |
|
dc.contributor.author |
Dogu, MH |
|
dc.contributor.author |
Yilmaz, M |
|
dc.contributor.author |
Kayikci, O |
|
dc.contributor.author |
Tombak, A |
|
dc.contributor.author |
Kuku, I |
|
dc.contributor.author |
Celebi, H |
|
dc.contributor.author |
Akay, MO |
|
dc.contributor.author |
Esen, R |
|
dc.contributor.author |
Korkmaz, S |
|
dc.contributor.author |
Keskin, A |
|
dc.date.accessioned |
2022-10-13T11:46:40Z |
|
dc.date.available |
2022-10-13T11:46:40Z |
|
dc.date.issued |
2015 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/79610 |
|
dc.description.abstract |
In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd. |
|
dc.description.abstract |
C1 [Hacioglu, Sibel; Dogu, Mehmet Hilmi; Keskin, Ali] Pamukkale Univ, Dept Hematol, TR-20070 Denizli, Turkey. |
|
dc.description.abstract |
[Bilen, Yusuf; Yildirim, Rahsan] Ataturk Univ, Dept Hematol, Erzurum, Turkey. |
|
dc.description.abstract |
[Eser, Ali] Marmara Univ, Dept Hematol, Istanbul, Turkey. |
|
dc.description.abstract |
[Sivgin, Serdar] Erciyes Univ, Dept Hematol, Kayseri, Turkey. |
|
dc.description.abstract |
[Gurkan, Emel] Cukurova Univ, Dept Hematol, Adana, Turkey. |
|
dc.description.abstract |
[Aydogdu, Ismet] Celal Bayar Univ, Dept Hematol, Manisa, Turkey. |
|
dc.description.abstract |
[Yilmaz, Mehmet] Gaziantep Univ, Dept Hematol, Gaziantep, Turkey. |
|
dc.description.abstract |
[Kayikci, Omur] Ankara Oncol Educ & Res Hosp, Dept Hematol, Ankara, Turkey. |
|
dc.description.abstract |
[Tombak, Anil] Mersin Univ, Dept Hematol, Mersin, Turkey. |
|
dc.description.abstract |
[Kuku, Irfan] Inonu Univ, Dept Hematol, Malatya, Turkey. |
|
dc.description.abstract |
[Celebi, Harika] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Hematol, Ankara, Turkey. |
|
dc.description.abstract |
[Akay, Meltem Olga] Osmangazi Univ, Dept Hematol, Eskisehir, Turkey. |
|
dc.description.abstract |
[Esen, Ramazan] Yuzuncu Yil Univ, Dept Hematol, Van, Turkey. |
|
dc.description.abstract |
[Korkmaz, Serdal] Cumhuriyet Univ, Dept Hematol, Sivas, Turkey. |
|
dc.source |
HEMATOLOGICAL ONCOLOGY |
|
dc.title |
Multicenter retrospective analysis regarding the clinical manifestations |
|
dc.title |
and treatment results in patients with hairy cell leukemia: twenty-four |
|
dc.title |
year Turkish experience in cladribine therapy |
|